Role of Icosapent Ethyl in Residual CV Risk

Espacio reservado para
la imagen del ponente
Residual cardiovascular risk:
what is the role of icosapent ethyl?
Prof. Xavier Garcia-Moll
Hospital de la Santa Creu i Sant Pau, Barcelona (Spain)

Espacio reservado para la imagen
del ponente
Xavier Garcia-Moll
Icosa pento de etilo (IPE): indications as per technical data sheet

del ponente
Xavier Garcia-Moll
Major randomised studies with EPA:
• REDUCE-IT
• EVAPORATE

del ponente
Xavier Garcia-Moll
REDUCE-IT trial
• Randomised trial; multicentric; double blind; controlled (statin + IPE 2 g/12h vs statin + placebo)
• 8179 patients with established cardiovascular disease (70.7% of all patients included) or with T2D and other CV risk
factors, under treatment with statins and with high serum triglycerides (135 - 499 mg/dL or 1.52 - 5.63 mmol/L)
• Mean follow up: 4.9 years
• Primary composite endpoint: CV death, non fatal MI, non fatal stroke, coronary revascularisation, or unstable angina
• Key secondary endpoint: composed of CV death, non fatal MI, or non fatal stroke
Bhatt DL, et al. N Engl J Med 2019;380:11-22

del ponente
Xavier Garcia-Moll
REDUCE-IT trial

del ponente
Xavier Garcia-Moll
REDUCE-IT trial
Primary composite endpoint: CV death, non fatal MI, non fatal stroke,
coronary revascularisation, or unstable angina Key secondary endpoint: CV death, non fatal MI or non fatal stroke
RRR=24.8%
ARR: 4.8%
NNT: 21 (95%CI 15-33)
28.3%
23.0% RRR=26.5%
ARR: 3.6%
NNT: 28 (95%CI 20-47)
20.0%
16.2%

del ponente
Xavier Garcia-Moll
REDUCE-IT trial

del ponente
REDUCE-IT trial
Safety:

del ponente
Xavier Garcia-Moll
Bhatt DL, et al. JACC. 2019;73:2791-2802
REDUCE-IT trial: pre-specified subgroup analysis
Total episodes reduction throughout study lenght

del ponente
Xavier Garcia-Moll
Bhatt DL, Steg PG, Miller M, et al., ESC 2021 (virtual)
Primary endpoint reduction in patients with prior MI

del ponente
Xavier Garcia-Moll
Primary endpoint reduction in patients with prior surgical revascularisation
Verma S, et al. Circulation. 2021;144:1845–1855.

del ponente
Xavier Garcia-Moll
Majithia A, et al. Circulation. 2021;144:1750–1759.
Primary endpoint reduction in patients depending on their renal function

del ponente
Xavier Garcia-Moll
Peterson BE, et al. Circulation. 2021;143:33–44.
39% reduction of urgent/emergent
revascularisation: first non anti-LDL molecule to
achieve these results
Reduction of revascularisations
Time to coronary revascularisation (urgent or elective) from randomisation: intention to treat analysis
Urgent and elective; first, second, third;
percutaneous or surgical

del ponente
Xavier Garcia-Moll
Arbel R, et al. Am J Med 2021; https://doi.org/10.1016/j.amjmed.2020.12.023
Primary Prevention Secondary Prevention
Control arm event rate 13.62% 25.51%
IPE Hazard Ratio (95% CI) 0.876 (0.7 – 1.095) 0.726 (0.65 – 0.81)
IPE arm event rate (95% CI) 13.62%*0.876 = 11.93%
(9.53% - 14.91%)
25.51%*0.726=18.52%
(16.58% - 20.68%)
Absolute risk reduction (%) (95% CI) 13.62%*11.93% = 1.689%
(4.085% - (-1.29%))
25.51%*18.52% = 6.976%
(4.87% - 8.95%)
Number needed to treat (95% CI) 1/1.689% = 59 (24 - ∞) 1/6.976% = 14 (11 – 21)
Primary endpoint reduction in Primary Prevention patients and in Secondary Prevention patients

del ponente
Xavier Garcia-Moll
Budoff MJ, et al. Eur Heart J;2020;41:3925–3932
EVAPORATE trial
• Randomised study, double blind, controlled (statin + EPA 4 g/day vs statin + placebo)
• 80 patients with coronary atherosclerosis as per coronary CT scan (1 or more stenoses ≥20%), treated with
statins and with triglycerides persistently high
• Coronary CT scan at month 9 and at the end of the study (18 months)
• Primary endpoint: change in volume of low-attenuation plaque (LAP) at month 18 between EPA group and
placebo group

del ponente
Xavier Garcia-Moll
EVAPORATE trial
Budoff MJ, et al. Eur Heart J;2020;41:3925–3932

del ponente
EMA indication for IPE:

del ponente
Mineral oil in placebo group in REDUCE-IT:

del ponente
Xavier Garcia-Moll
Tokgozoglu L, et al. Eur Heart J 2021; doi:10.1093/eurheartj/ehab875

del ponente
Xavier Garcia-Moll
Dawson, L.P. et al. J Am Coll Cardiol. 2022;79(1):66–82.

del ponente
Xavier Garcia-Moll
• EUROASPIRE Risk Calculator: https://www.calconic.com
• SMART-REACH calculator: u-prevent.com
• DIAL model: Berkelmans GFN, et al. Eur Heart J 2019;40(34):2899-2906

del ponente
Xavier Garcia-Moll

del ponente
Xavier Garcia-Moll
Conclusions
From a clinical perspective:
• REDUCE-IT trial reduces main endpoint by 25% (HR 0.75; NNT 21)
• REDUCE-IT trial reduces secondary endpoint by 28% (HR 0.76; NNT 28)
• When compared with placebo, 4 g a day de icosapent etil reduced
• 20% CV death
• 31% MI
• 28% stroke
• NNT in secondary prevention to prevent an episode of the main endpoint was 14
• Coronary anatomy studies have shown that it modifies plaque composition
• In addition of lowering serum triglycerides, there is a clinical benefit

del ponente
Xavier Garcia-Moll
What do guidelines recommend:
• It is recommended to assess residual risk in high CV risk patients
• It is important to measure non-HDL cholesterol and triglycerides in patients with
high CV risk
• In high CV risk patients with LDL-cholesterol levels within range, treatment of high
triglycerides receive IIA/ IIB recommendations in the ESC guidelines
Conclusions -2-

del ponente
Xavier Garcia-Moll
Thank you for your attention
@xgmoll

Role of Icosapent Ethyl in Residual CV Risk

Recomendados

Recomendados

Más contenido relacionado

La actualidad más candente

La actualidad más candente (20)

Similar a Role of Icosapent Ethyl in Residual CV Risk

Similar a Role of Icosapent Ethyl in Residual CV Risk (20)

Más de Sociedad Española de Cardiología

Más de Sociedad Española de Cardiología (20)

Último

Último (20)

Role of Icosapent Ethyl in Residual CV Risk